De Novo Solid Tumors after Kidney Transplantation: Is It Time for a Patient-Tailored Risk Assessment? Experience from a Single Center

A. Rossetto, P. Tulissi, F. De Marchi, M. Gropuzzo, C. Vallone, G. L. Adani, U. Baccarani, D. Lorenzin, D. Montanaro, A. Risaliti

Research output: Contribution to journalArticle

Abstract

Background Progress in immunosuppressive therapy and perioperative techniques has improved the survivals of both grafts and patients. The patient, however, is exposed to the risks of aging and side effects of immunosuppression. De novo tumors are the 2nd cause of death in the organ transplant population. The aim of this study was to evaluate whether the current accepted guidelines for the pre-transplantation study and the post-transplantation follow-up have been effective, in our kidney transplant population, regarding early detection and treatment, improving prognosis, and reducing mortality of some curable neoplastic diseases. Methods We considered de novo tumors in kidney transplant patients from 1995 to 2010 (n = 636) excluding hematologic and nonmelanoma skin tumors from our study. Results There were 64 de novo tumors in 59 patients out of 636 kidney transplant patients; 29.68% were urogenital cancer, 26.56% gastrointestinal cancer, 12.5% melanoma, 6.25% lung cancer, 6.25% biliopancreatic cancer, 4.68% visceral Kaposi sarcoma, 4.68% breast cancer, 4.68% thyroid cancer, 1 pleural mesothelioma, 1 meningioma, 1 merkeloma. Twenty patients died because of cancer. Ten patients had a late de novo tumor diagnosis, when the stage of tumor was advanced and not suitable for curative treatment. Conclusions Because of the increased neoplastic risk, we consider it mandatory to carry out a meticulous screening and to implement pre-transplantation study concerning this increased neoplastic risk population to detect a subgroup of patients presenting the highest risk to improve their outcome.

Original languageEnglish
Pages (from-to)2116-2120
Number of pages5
JournalTransplantation Proceedings
Volume47
Issue number7
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Kidney Transplantation
Neoplasms
Transplants
Transplantation
Kidney
Thyroid Neoplasms
Urogenital Neoplasms
Population
Gastrointestinal Neoplasms
Kaposi's Sarcoma
Mesothelioma
Meningioma
Graft Survival
Immunosuppressive Agents
Immunosuppression
Cause of Death
Melanoma
Lung Neoplasms
Therapeutics
Guidelines

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

De Novo Solid Tumors after Kidney Transplantation : Is It Time for a Patient-Tailored Risk Assessment? Experience from a Single Center. / Rossetto, A.; Tulissi, P.; De Marchi, F.; Gropuzzo, M.; Vallone, C.; Adani, G. L.; Baccarani, U.; Lorenzin, D.; Montanaro, D.; Risaliti, A.

In: Transplantation Proceedings, Vol. 47, No. 7, 01.09.2015, p. 2116-2120.

Research output: Contribution to journalArticle

Rossetto, A, Tulissi, P, De Marchi, F, Gropuzzo, M, Vallone, C, Adani, GL, Baccarani, U, Lorenzin, D, Montanaro, D & Risaliti, A 2015, 'De Novo Solid Tumors after Kidney Transplantation: Is It Time for a Patient-Tailored Risk Assessment? Experience from a Single Center', Transplantation Proceedings, vol. 47, no. 7, pp. 2116-2120. https://doi.org/10.1016/j.transproceed.2015.01.029
Rossetto, A. ; Tulissi, P. ; De Marchi, F. ; Gropuzzo, M. ; Vallone, C. ; Adani, G. L. ; Baccarani, U. ; Lorenzin, D. ; Montanaro, D. ; Risaliti, A. / De Novo Solid Tumors after Kidney Transplantation : Is It Time for a Patient-Tailored Risk Assessment? Experience from a Single Center. In: Transplantation Proceedings. 2015 ; Vol. 47, No. 7. pp. 2116-2120.
@article{ce1cb58f32854d11ae918bf7ad9620d3,
title = "De Novo Solid Tumors after Kidney Transplantation: Is It Time for a Patient-Tailored Risk Assessment? Experience from a Single Center",
abstract = "Background Progress in immunosuppressive therapy and perioperative techniques has improved the survivals of both grafts and patients. The patient, however, is exposed to the risks of aging and side effects of immunosuppression. De novo tumors are the 2nd cause of death in the organ transplant population. The aim of this study was to evaluate whether the current accepted guidelines for the pre-transplantation study and the post-transplantation follow-up have been effective, in our kidney transplant population, regarding early detection and treatment, improving prognosis, and reducing mortality of some curable neoplastic diseases. Methods We considered de novo tumors in kidney transplant patients from 1995 to 2010 (n = 636) excluding hematologic and nonmelanoma skin tumors from our study. Results There were 64 de novo tumors in 59 patients out of 636 kidney transplant patients; 29.68{\%} were urogenital cancer, 26.56{\%} gastrointestinal cancer, 12.5{\%} melanoma, 6.25{\%} lung cancer, 6.25{\%} biliopancreatic cancer, 4.68{\%} visceral Kaposi sarcoma, 4.68{\%} breast cancer, 4.68{\%} thyroid cancer, 1 pleural mesothelioma, 1 meningioma, 1 merkeloma. Twenty patients died because of cancer. Ten patients had a late de novo tumor diagnosis, when the stage of tumor was advanced and not suitable for curative treatment. Conclusions Because of the increased neoplastic risk, we consider it mandatory to carry out a meticulous screening and to implement pre-transplantation study concerning this increased neoplastic risk population to detect a subgroup of patients presenting the highest risk to improve their outcome.",
author = "A. Rossetto and P. Tulissi and {De Marchi}, F. and M. Gropuzzo and C. Vallone and Adani, {G. L.} and U. Baccarani and D. Lorenzin and D. Montanaro and A. Risaliti",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.transproceed.2015.01.029",
language = "English",
volume = "47",
pages = "2116--2120",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "7",

}

TY - JOUR

T1 - De Novo Solid Tumors after Kidney Transplantation

T2 - Is It Time for a Patient-Tailored Risk Assessment? Experience from a Single Center

AU - Rossetto, A.

AU - Tulissi, P.

AU - De Marchi, F.

AU - Gropuzzo, M.

AU - Vallone, C.

AU - Adani, G. L.

AU - Baccarani, U.

AU - Lorenzin, D.

AU - Montanaro, D.

AU - Risaliti, A.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background Progress in immunosuppressive therapy and perioperative techniques has improved the survivals of both grafts and patients. The patient, however, is exposed to the risks of aging and side effects of immunosuppression. De novo tumors are the 2nd cause of death in the organ transplant population. The aim of this study was to evaluate whether the current accepted guidelines for the pre-transplantation study and the post-transplantation follow-up have been effective, in our kidney transplant population, regarding early detection and treatment, improving prognosis, and reducing mortality of some curable neoplastic diseases. Methods We considered de novo tumors in kidney transplant patients from 1995 to 2010 (n = 636) excluding hematologic and nonmelanoma skin tumors from our study. Results There were 64 de novo tumors in 59 patients out of 636 kidney transplant patients; 29.68% were urogenital cancer, 26.56% gastrointestinal cancer, 12.5% melanoma, 6.25% lung cancer, 6.25% biliopancreatic cancer, 4.68% visceral Kaposi sarcoma, 4.68% breast cancer, 4.68% thyroid cancer, 1 pleural mesothelioma, 1 meningioma, 1 merkeloma. Twenty patients died because of cancer. Ten patients had a late de novo tumor diagnosis, when the stage of tumor was advanced and not suitable for curative treatment. Conclusions Because of the increased neoplastic risk, we consider it mandatory to carry out a meticulous screening and to implement pre-transplantation study concerning this increased neoplastic risk population to detect a subgroup of patients presenting the highest risk to improve their outcome.

AB - Background Progress in immunosuppressive therapy and perioperative techniques has improved the survivals of both grafts and patients. The patient, however, is exposed to the risks of aging and side effects of immunosuppression. De novo tumors are the 2nd cause of death in the organ transplant population. The aim of this study was to evaluate whether the current accepted guidelines for the pre-transplantation study and the post-transplantation follow-up have been effective, in our kidney transplant population, regarding early detection and treatment, improving prognosis, and reducing mortality of some curable neoplastic diseases. Methods We considered de novo tumors in kidney transplant patients from 1995 to 2010 (n = 636) excluding hematologic and nonmelanoma skin tumors from our study. Results There were 64 de novo tumors in 59 patients out of 636 kidney transplant patients; 29.68% were urogenital cancer, 26.56% gastrointestinal cancer, 12.5% melanoma, 6.25% lung cancer, 6.25% biliopancreatic cancer, 4.68% visceral Kaposi sarcoma, 4.68% breast cancer, 4.68% thyroid cancer, 1 pleural mesothelioma, 1 meningioma, 1 merkeloma. Twenty patients died because of cancer. Ten patients had a late de novo tumor diagnosis, when the stage of tumor was advanced and not suitable for curative treatment. Conclusions Because of the increased neoplastic risk, we consider it mandatory to carry out a meticulous screening and to implement pre-transplantation study concerning this increased neoplastic risk population to detect a subgroup of patients presenting the highest risk to improve their outcome.

UR - http://www.scopus.com/inward/record.url?scp=84940999390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940999390&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2015.01.029

DO - 10.1016/j.transproceed.2015.01.029

M3 - Article

C2 - 26361657

AN - SCOPUS:84940999390

VL - 47

SP - 2116

EP - 2120

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 7

ER -